- Home
- CDXS
CDXS
Codexis Inc.
as 12-20-2024 4:00pm EST
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 332.0M | IPO Year: | 2010 |
| Target Price: | $11.00 | AVG Volume (30 days): | 875.4K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.53 - $6.08 | Next Earning Date: | 10-31-2024 |
| Revenue: | $64,446,000 | Revenue Growth: | -12.86% |
| Revenue Growth (this year): | -5.06% | Revenue Growth (next year): | 2.02% |
Stock Insider Trading Activity of Codexis Inc. (CDXS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | CDXS | 10% Owner | Oct 25 '24 | Buy | $2.91 | 25,000 | $72,720.00 | 8,545,000 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Sep 24 '24 | Buy | $2.90 | 85,000 | $249,146.50 | 8,545,000 |
Latest Codexis Inc. News
CDXS Breaking Stock News: Dive into CDXS Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
Codexis, Inc.'s (NASDAQ:CDXS) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week
GlobeNewswire
16 days ago
Codexis Announces New Employment Inducement Grants
GlobeNewswire
a month ago
Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire
a month ago
Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics
GlobeNewswire
a month ago
Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors
GlobeNewswire
a month ago
Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics
GlobeNewswire
a month ago
Codexis Announces New Employment Inducement Grants
GlobeNewswire
2 months ago
Codexis to Participate in Upcoming Healthcare Conferences
Compare CDXS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CDXS Codexis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.